Sharon L. Wienbar
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
Enovis joins AAOS Registry Program as industry sponsor. Enovis has become the first multi-registry industry sponsor of the AAOS Registry Program. This move highlights the company's engagement with major orthopedic data initiatives. The stock is currently trading near its 52-week low, with an average analyst target of $38.33.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
Ingram Micro (INGM) in focus after Opengear deal and analyst coverage. Recent Yahoo articles list INGM among Wall Street's favored stocks while noting some headwinds. Analysts compare its valuation to peers and point to the Opengear partnership that expands its AI infrastructure role in Europe, suggesting the stock may be undervalued. The coverage highlights potential upside as the price sits near a key support level.
Transaction History
| REZI | ▲ Buy | Grant | 5,468 | $0 | 6/3/2026 | View on chart |
| ENOV | ▲ Buy | Grant | 9,346 | $0 | 5/19/2026 | View on chart |
| INGM | ▲ Buy | Grant | 7,031 | $0 | 5/14/2026 | View on chart |
| INGM | ▲ Buy | Grant | 9,615 | $0 | 6/4/2025 | View on chart |
| REZI | ▲ Buy | Grant | 7,887 | $0 | 6/4/2025 | View on chart |
| ENOV | ▲ Buy | Grant | 6,598 | $0 | 5/21/2025 | View on chart |
| INGM | ▲ Buy | Grant | 8,409 | $0 | 10/23/2024 | View on chart |
| REZI | ▲ Buy | Grant | 7,600 | $0 | 6/5/2024 | View on chart |
| ENOV | ▲ Buy | Grant | 4,338 | $0 | 5/20/2024 | View on chart |
| REZI | ▲ Buy | Grant | 9,158 | $0 | 6/7/2023 | View on chart |
| ENOV | ▲ Buy | Grant | 1,875 | $0 | 5/16/2023 | View on chart |
| REZI | ▲ Buy | Grant | 1,752 | $29K | 1/3/2023 | View on chart |
| ENOV | ▲ Buy | Grant | 421 | $0 | 12/30/2022 | View on chart |
| REZI | ▲ Buy | Grant | 1,497 | $29K | 10/3/2022 | View on chart |
| ENOV | ▲ Buy | Grant | 489 | $0 | 9/30/2022 | View on chart |
| REZI | ▲ Buy | Grant | 1,516 | $29K | 7/1/2022 | View on chart |
| ENOV | ▲ Buy | Grant | 410 | $0 | 6/30/2022 | View on chart |
| REZI | ▲ Buy | Grant | 6,280 | $0 | 6/8/2022 | View on chart |
| ENOV | ▲ Buy | Grant | 1,648 | $0 | 6/7/2022 | View on chart |
| ENOV | ▲ Buy | Grant | 336 | $0 | 4/18/2022 | View on chart |
| REZI | ▲ Buy | Grant | 1,189 | $29K | 4/1/2022 | View on chart |
| ENOV | ▲ Buy | Grant | 490 | $0 | 12/31/2021 | View on chart |
| REZI | ▲ Buy | Option Exercise | 5,578 | $0 | 11/16/2021 | View on chart |
| ENOV | ▲ Buy | Grant | 491 | $0 | 9/30/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
Apple Smart Home Moves Press Resideo Stock
Resideo shares fell as reports of Apple's expanding smart home plans raised competitive concerns for the company. This news coincided with a broader drop in related stocks like Arlo and Allegion. The stock is currently trading near its 52-week low, reflecting significant market pressure despite a low P/E ratio.
Apple Smart Home Moves Press Resideo Stock. Resideo shares fell as reports of Apple's expanding smart home plans raised competitive concerns for the company. This news coincided with a broader drop in related stocks like Arlo and Allegion. The stock is currently trading near its 52-week low, reflecting significant market pressure despite a low P/E ratio.